$ 23.99Add to cart
Pirazidol (Pyrazidolum) - antidepressant.
Selectively inhibits MAO Type A blocks deamination of serotonin and noradrenaline, to a lesser extent - tyramine. Partially inhibits the reuptake of monoamines, potentiates the effects of norepinephrine precursor - dihydroxyphenylalanine (L-dopa) and serotonin precursor - 5 oksitriptofana. It stimulates the adrenergic and serotonergic structures. It activates the processes of synaptic transmission of nerve excitation in the central nervous system. Nootropic effect, improves cognitive function.
Pirazidol - the original Russian antidepressant, a reversible inhibitor of monoamine oxidase type A are similar in structure and spectrum antidepressant actions are tetrindol and inkazan. According to Russian authors, different regulatory effects on the central nervous system (shows the activating effect in patients with apathetic, anergic depression and sedation in patients with agitated states). In addition, it is alleged that pirazidol also possesses nootropic activity and enhances cognitive (cognitive) function . Structurally pirazidol is similar to serotonin
Depression, including senile, involutional, occurring primarily with psychomotor retardation and asthenic disorders, anxiety, depression or anxiety and delusional components, alcohol withdrawal syndrome, Alzheimer's disease (in the complex therapy).
Pirazidol not prescribed in conjunction with antidepressant MAO-inhibitors, furazolidone, procarbazine, selegiline.
Perhaps the use of pirazidol in patients with glaucoma and benign prostatic hyperplasia.
Pirazidol compatible with antipsychotics, anxiolytics.
It improves the effectiveness of epinephrine (due to antimonoaminoksidaznoy activity). Compatible with antipsychotics, anxiolytics. Incompatible with antidepressants - MAO inhibitors, furazolidone, procarbazine, selegiline.
Inside, 0,05-0,075 g / day in 2 divided doses, gradually increasing the dose of 0.025-0.05 g and 0.15-0.30 g / day. The maximum daily dose - 0.4 g, divided into 2-3 doses. After achieving a therapeutic effect in the treatment is continued for 2-4 weeks after which the dose is gradually reduced.
Important notice- the outer box design may vary before prior notice!